Endoscopic sclerotherapy of esophageal varices has gained worldwide popularity. There is a consensus that sclerotherapy is an effective treatment for temporarily controlling acute variceal hemorrhage. Sclerotherapy has no place in the routine prophylaxis before the index bleed. The role of long-term sclerotherapy to prevent rebleeding is debatable. It is our bias that once patients with cirrhosis suffer a variceal hemorrhage, they should be considered for liver transplantation. If they are not suitable candidates for transplantation and have mild to moderate hepatic dysfunction, then portosystemic shunting provides definitive secondary prophylaxis against rebleeding. Sclerotherapy should be reserved for patients with advanced decompensated cirrhosis.